ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.25.

A number of research firms recently weighed in on PRQR. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Oppenheimer started coverage on ProQR Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price objective on the stock. Chardan Capital reiterated a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Thursday, April 9th. Wall Street Zen downgraded ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings upgraded ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 8th.

Hedge Funds Weigh In On ProQR Therapeutics

Several large investors have recently bought and sold shares of PRQR. Jane Street Group LLC raised its position in ProQR Therapeutics by 699.3% in the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 79,720 shares during the last quarter. Bank of America Corp DE grew its stake in ProQR Therapeutics by 25.7% during the second quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 24,347 shares during the period. BNP Paribas Financial Markets grew its stake in ProQR Therapeutics by 28.4% during the second quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 26,893 shares during the period. Osaic Holdings Inc. grew its stake in ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares during the period. Finally, Aberdeen Group plc boosted its holdings in ProQR Therapeutics by 24.2% in the third quarter. Aberdeen Group plc now owns 2,298,823 shares of the biopharmaceutical company’s stock worth $4,896,000 after acquiring an additional 448,475 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Price Performance

NASDAQ:PRQR opened at $1.89 on Monday. The firm has a market capitalization of $199.13 million, a price-to-earnings ratio of -3.78 and a beta of 0.07. ProQR Therapeutics has a twelve month low of $1.33 and a twelve month high of $3.10. The stock’s 50 day moving average price is $1.62 and its two-hundred day moving average price is $1.72.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). The firm had revenue of $2.35 million for the quarter, compared to analyst estimates of $5.19 million. ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%. As a group, analysts anticipate that ProQR Therapeutics will post -0.57 earnings per share for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.